For example, we reported that Rapalink-1, a next-generation mammalian target of rapamycin inhibitor, has greater tumor-suppressive effects than temsirolimus against sunitinib-resistant RCC cells [12] and that SCG2 regulates angiogenesis in sunitinib-resistant RCC via the VHL/hypoxia-inducible factor/VEGF pathway [13]. This evidence concerns the gene SCG2 and neoplasm.